Fewer than 7% of U.S. adults meet the criteria for optimal cardiometabolic health, according to a JACC analysis of more than 55,000 people highlighted by Harvard Health. That share has declined over the past two decades.
Most discussions treat heart risk and metabolic risk as separate tracks. Better consumer content explains that isolated numbers do not tell the whole story, but it rarely explains why those numbers start moving together. After 40, one of the most significant and least discussed drivers is hormonal aging: estrogen loss at menopause and gradual testosterone decline in men. Diet and willpower are not the whole story.
This article translates the American Heart Association’s Cardiovascular-Kidney-Metabolic (CKM) framework into plain language. It then shows how hormone decline moves people through its stages and explains why ongoing, hormone-aware monitoring is the most practical long-term strategy.
Cardio-Metabolic Health, Briefly Redefined
Cardio-metabolic health is the combined function of the heart, the blood vessels, and the body’s energy-use system. It cannot be captured by a single number on a lab report.
The more useful question is why weight, cholesterol, blood sugar, and blood pressure tend to shift together. The scale of the problem is significant. According to a 2026 epidemiology review, nearly 49% of U.S. adults (about 130.6 million people) meet criteria for cardiovascular disease when hypertension is included, yet fewer than 11% meet criteria for optimal CKM health.
Timing is a key piece that often gets overlooked. These markers tend to shift in the same decade for both men and women, roughly beginning in the 40s.
The AHA’s CKM Framework, Translated into Plain Language
In 2023, the American Heart Association introduced Cardiovascular-Kidney-Metabolic (CKM) Syndrome. It is a staged model that is now central to the 2026 AHA/ACC/ADA/ASN clinical guidelines. In simplified terms, the stages are:
- Stage 0: No risk factors. Weight, glucose, blood pressure, lipids, and kidney function are all normal.
- Stage 1: Excess or dysfunctional body fat, particularly abdominal fat.
- Stage 2: Metabolic risk factors such as high blood pressure, elevated triglycerides, diabetes, or chronic kidney disease.
- Stage 3: Subclinical cardiovascular disease, meaning damage is present but has not yet caused symptoms.
- Stage 4: Clinical cardiovascular disease, with or without kidney failure.
The framework formally merges heart disease, kidney disease, diabetes, and obesity into one continuum. The stakes are real: nearly 65% of U.S. adults aged 65 and older are already in Stages 2 to 4, and underrepresented racial and ethnic groups are disproportionately affected.
The strategic point is that proactive care is not about one good lab result. Its goal is staying in the earliest stages for as many decades as possible.
Why the 40s Are a Turning Point, Not a Coincidence
Hormonal aging accelerates CKM progression. It is a distinct factor, but it compounds the effects of lifestyle and genetics. In the All of Us Research Program, which included 126,892 adults, men had significantly higher odds of elevated CKM stage than women (OR 1.58). Hormone trajectories differ by sex, but they lead to the same risk markers.
The core thesis is straightforward. Estrogen loss after menopause and testosterone decline in men both reshape LDL, visceral fat, insulin sensitivity, blood pressure, and vascular function. These are the same markers that define CKM stage.
Women: Menopause as a Cardiometabolic Transition
Research published in The Lancet Diabetes & Endocrinology describes menopause as a cardiometabolic transition. Estrogen’s protective effect fades roughly 10 years after menopause onset. This coincides with adverse shifts in LDL, visceral fat, insulin sensitivity, and vascular function.
Declining estradiol and SHBG (sex hormone-binding globulin) correlate with worsening components of metabolic syndrome. A nuance rarely covered in mainstream content: a higher testosterone-to-estradiol (T/E2) ratio in postmenopausal women is associated with greater prevalence of cardiometabolic disease. This is a gradual, systemic shift rather than a single symptom, and one-time testing tends to miss it.
Men: Andropause and the Slow Erosion of Cardiometabolic Resilience
Bioavailable testosterone declines by about 2% per year starting in midlife, a process often called andropause. Low testosterone has been linked epidemiologically to inflammation, insulin resistance, dyslipidemia, and atherosclerosis.
Because the decline is gradual, it is often dismissed as “normal aging.” As a result, it is monitored far less than more visible markers such as weight. For men, the concern is not appearance. It is energy, strength, and long-term cardiovascular resilience.
The Shared Markers: How Hormone Decline Rewrites the Same Risk Profile
Hormone decline follows different pathways in men and women, but in both sexes it affects the same list of markers.
LDL and Lipid Shifts
Estrogen loss and testosterone decline each disrupt lipid metabolism on their own, pushing LDL and related markers in an unfavorable direction. An isolated LDL screening without hormonal context may flag the number but miss the underlying driver of the trend.
Visceral Fat Redistribution
Hormonal aging changes where the body stores fat. After 40, both sexes tend to store more visceral (abdominal) fat and less subcutaneous fat. In postmenopausal women, testosterone and DHT decrease as waist-to-hip ratio rises, while estradiol and estrone increase with BMI. This shows that the relationship between hormones and fat runs in both directions. Because visceral fat is directly relevant to the adiposity criteria in CKM staging, this shift matters clinically.
Insulin Sensitivity and Blood Pressure
In both sexes, declining sex hormones are linked to reduced insulin sensitivity and rising blood pressure over time. These are the markers that define progression from Stage 1 to Stage 2.
Vascular Function
Estrogen and testosterone both support healthy endothelial function, which is the health of the inner lining of blood vessels. As these hormones decline, arteries tend to stiffen and lose resilience. Vascular function is the “quiet” marker: it is rarely tested in routine checkups, yet it is central to long-term cardiovascular risk.
What the Latest Clinical Evidence Says About Hormone Therapy and Heart Risk
A natural question follows: isn’t hormone therapy risky for the heart? The TRAVERSE trial (NEJM, 2023) enrolled 5,246 hypogonadal men aged 45 to 80 with elevated cardiovascular risk. It found that testosterone replacement therapy was non-inferior to placebo for major adverse cardiovascular events. Follow-up analyses, however, identified increased risk signals for erythrocytosis (elevated red blood cell counts) and atrial fibrillation.
Both findings matter. The trial eased earlier FDA-driven safety concerns, and it also showed why hormone therapy calls for monitoring. TRAVERSE does not support blanket endorsement or reflexive avoidance. It supports individualized, clinically supervised decisions.
Where GLP-1 Medications Fit Into the Cardio-Metabolic Picture
GLP-1 receptor agonists have become a major development in cardiometabolic care. Large cardiovascular outcomes trials of FDA-approved GLP-1 medications have shown benefits related to major adverse cardiovascular events. These effects appear to be partly independent of weight loss and may involve improved endothelial function and reduced inflammation.
Why a Single Test or Program Can’t Keep You in Early CKM Stages
Hormone decline is gradual and continuous. A one-time lab panel or a single weight-loss program captures a snapshot, not a trajectory.
Untracked risk compounds over time. Among patients with CKM-related heart failure, 84% to 87% have at least one major cardiometabolic comorbidity, and roughly two-thirds have chronic kidney disease, diabetes, or both. These conditions build up over years, not months. On the positive side, a UK Biobank study of more than 135,000 people linked optimal cardiometabolic health to more years lived free of cardiovascular disease, diabetes, cancer, and dementia. That is an argument about health-span, not only lifespan.
The practical answer is ongoing, hormone-aware monitoring: tracking lipids, visceral fat, insulin sensitivity, blood pressure, vascular markers, and hormone levels together over time. This approach differs from lab-testing services that diagnose without treating. It also differs from premium longevity clinics that rely on expensive imaging without integrating hormone care.
How Red Mountain Approaches Long-Term Cardio-Metabolic Monitoring
Red Mountain’s Function and Longevity/Maintenance stages are designed for this problem. The Function stage focuses on restoring how the body works. The Longevity/Maintenance stage focuses on protecting that progress over the next 10 to 20 years.
Hormone optimization for men and women, metabolic assessment, body-composition tracking, and preventive labs work together as one system rather than as separate services. This approach is grounded in more than 30 years of real-world patient outcomes, in-person providers at brick-and-mortar clinics, and a clinical model built for long-term relationships rather than one-time interventions. Hormone therapy and GLP-1 medications are tools within that structure. Clinical monitoring and support are what make the plan work.
Conclusion: Treating Hormones and Heart Risk as One System
Cardio-metabolic risk after 40 cannot be fully understood without accounting for hormonal aging. Estrogen loss in women and testosterone decline in men both reshape the markers that define CKM stage. The CKM framework gives patients and clinicians a shared language for discussing risk. Staying in the early stages, however, requires sustained attention over time rather than a single test or intervention. This is proactive, long-horizon health management, not crisis response.
Next Step: Understanding Your Own Cardio-Metabolic and Hormonal Trajectory
For readers who recognize these patterns in their own labs or history, a consult is usually the next step. In a consult, Red Mountain clinicians explain how hormone-aware monitoring applies to an individual’s trajectory. The work draws on decades of clinical experience and is focused on long-term metabolic correction and body optimization, not on a single product or program.
Red Mountain may prescribe a compounded version of a GLP-1. Compounded GLP-1s contain semaglutide or tirzepatide. Compounded GLP-1s have not been approved by the FDA or reviewed by the FDA for safety, effectiveness, or quality. Compounded GLP-1s have not been demonstrated to the FDA to be safe or effective for weight loss. Compounded GLP-1s manufacturing processes have not been reviewed by the FDA. FDA-approved products containing semaglutide and tirzepatide are available. Ask your provider for more information.